Open AccessEffects of Gastrointestinal-Type Chemotherapy in Women With Ovarian Mucinous Carcinoma
Author(s) -
Katherine C. Kurnit,
Abdulrahman K. Sinno,
Bryan Fellman,
Aaron Varghese,
Rebecca L. Stone,
Anil K. Sood,
David M. Gershenson,
Kathleen M. Schmeler,
Anaís Malpica,
Amanda N. Fader,
Michael Frumovitz
Publication year - 2019
Publication title -
obstetrics and gynecology (new york. 1953. online)/obstetrics and gynecology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.664
H-Index - 220
eISSN - 1873-233X
pISSN - 0029-7844
DOI - 10.1097/aog.0000000000003579
Subject(s) - medicine , oxaliplatin , bevacizumab , oncology , chemotherapy , irinotecan , gastrointestinal cancer , hazard ratio , regimen , ovarian carcinoma , ovarian cancer , mucinous carcinoma , gynecologic oncology , gastroenterology , surgery , colorectal cancer , cancer , adenocarcinoma , confidence interval
To estimate whether gastrointestinal-type chemotherapy was associated with improved survival compared with standard gynecologic regimens for women with ovarian mucinous carcinoma.